drugset / Trial / NCT00904735

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

NCT00904735

Phase 2 Unknown 76 enrolled San Raffaele Scientific Institute
RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hydroxyurea is more effective when given alone or together with imatinib mesylate in treating patients with meningioma. PURPOSE: This randomized phase II trial is studying how well hydroxyurea works compared with giving hydroxyurea together with imatinib mesylate in treating patients with recurrent or progressive meningioma.

Timeline

Start
2009-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule Oral
Background Hydroxyurea Other / unclassified Oral